UNSPSC 51282137: Propicillin potassium

This classification denotes a penicillin antibiotic with the molecular structure C18H21N2O5S.K, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 75RXW2P83Y chemically known as (2s,5r,6r)-3,3-dimethyl-7-oxo-6-((1-oxo-2-phenoxybutyl)amino)-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid potassium salt, but more commonly known as propicillin potassium, which bears US NIH Compound Identifier 92878.

UNSPSC 51282137 Propicillin potassium is a Commodity code that nominally identifies a specific antibiotic agent, but recent state and local solicitation activity under this code shows little alignment with that narrow scope. The two most recent opportunities tagged to this code — a completed Illinois Department of Public Health pharmaceutical warehouse award for Doxycycline Hyclate and Ciprofloxacin Hydrochloride, and a Seminole County, Florida procurement for Naloxone and drug deactivation systems — do not reflect propicillin potassium or closely related penicillin derivatives. The code appears to function as a catch-all or misclassified category for sporadic pharmaceutical and health-supply purchases by state health departments and county community health programs rather than a meaningful category for vendors specializing in propicillin potassium products.

Issuing bodies under this code include state-level health agencies and county health departments using consortium purchasing vehicles and competitive sealed bidding. Recent activity spans Illinois and Florida; the Illinois Department of Public Health awarded a $2,999,999.11 three-year pharmaceutical supply contract to Chartwell Rx LLC through the MMCAP Infuse cooperative purchasing consortium on August 28, 2026, under an Invitation for Bid process, while Seminole County released an IFB on June 30, 2026 (response due July 26, 2023 — an evident date error in the source) for annual procurement of 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems with quarterly deliveries required. Neither opportunity directly aligns with the code's nominal pharmaceutical category. Given the mismatch between the code definition and recent solicitation content, pursuit of opportunities under this code should focus on verification of actual product requirements at issuance rather than reliance on the UNSPSC classification.